source
- Novartis encounters setbacks while AI firm Anthropic searches for a dealmakerThe latest Endpoints Weekly edition highlights a difficult period for Novartis, noting that the company is facing a series of setbacks. Details of the challenges are not provided, but the report s…
- Cullinan and Taiho report six-month survival gain for EGFR exon 20 NSCLC in phase 3 trialCullinan Therapeutics and Taiho Oncology presented interim data from their phase 3 Rezilient3 study, which evaluated the tyrosine kinase inhibitor zipalertinib combined with platinum‑based chemothe…